A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes

IMPORTANCE: Based on efficacy results from pivotal randomized clinical trials, PD-1 (programmed cell death 1) inhibitors, such as nivolumab and pembrolizumab, have been approved to treat various cancers. Response patterns with varying effects on progression-free survival (PFS) and overall survival (...

Descripción completa

Detalles Bibliográficos
Autores principales: Gyawali, Bishal, Hey, Spencer Phillips, Kesselheim, Aaron S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2018
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324401/
https://www.ncbi.nlm.nih.gov/pubmed/30646078
http://dx.doi.org/10.1001/jamanetworkopen.2018.0416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324401/
https://www.ncbi.nlm.nih.gov/pubmed/30646078
http://dx.doi.org/10.1001/jamanetworkopen.2018.0416

Ejemplares similares